Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diffuse large B-cell lymphoma (DLBCL)
Pharma
Incyte to seek FDA approval for Monjuvi in front-line DLBCL
Even if Monjuvi got its FDA approval in first-line DLBCL, analysts at William Blair said they “remain cautious on ultimate market share.”
Angus Liu
Jan 5, 2026 10:40am
ASH: Regeneron eyes simpler regimens to grow bispecifics' reach
Dec 8, 2025 8:00am
FDA rejects Roche's earlier DLBCL bid over lackluster US data
Jul 18, 2025 1:32pm
China approves 4 new drugs, including global 1st-in-class
Jul 2, 2025 11:32am
Roche’s bispecific-ADC combo keeps lymphoma at bay
Jun 23, 2025 10:27am
FDA leaders push for more US enrollment in cancer trials
May 20, 2025 12:52pm
